CompletedNCT00232687
Switching from risperidone to aripiprazole for schizophrenia
About this title
A Switch Study of BMS-337039 in Schizophrenic Out-patients
Read the official source — NCT00232687Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Hall in Tirol and 71 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: June 1, 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 450
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- France, United Kingdom, Belgium, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00232687
- Official title
Show the full official title
A Comparative, Randomized, Open-Label, Multicenter Study on the Efficacy and Safety of Switch Treatment With Aripiprazole in Schizophrenic Out-patients Who Are Experiencing Insufficient Efficacy With Risperidone and/or Safety and Tolerability Issues, While on Risperidone
Get this study by email
Recruitment & locations
CompletedHall in Tirol, Austria · Vienna, Austria · Bruges, Belgium
70 more locations
- Brussels, Belgium
- Diest, Belgium
- Halle, Belgium
- Sint-Denijs-Westrem, Belgium
- Stokrooie, Belgium
- Havířov, Czechia
- Olomouc, Czechia
- Prague, Czechia
- Přerov, Czechia
- Aubagne, France
- Bordeaux, France
- Brumath, France
- Château-Gontier, France
- Clermont-Ferrand, France
- Dijon, France
- Dommartin-lès-Toul, France
- Fains-Véel, France
- Hénin-Beaumont, France
- Le Pecq, France
- Lyon, France
- Poitiers, France
- Reims, France
- Roubaix, France
- Toulon, France
- Toulouse, France
- Achim, Germany
- Bochum, Germany
- Cologne, Germany
- Ellwangen, Germany
- Hattingen, Germany
- Nuremberg, Germany
- Osnabrück, Germany
- Ostfildern, Germany
- Witten, Germany
- Athens, Greece
- Chania, Greece
- Corfu, Greece
- Kalymnos, Greece
- Thessaloniki, Greece
- Tripoli, Greece
- Baja, Hungary
- Eger, Hungary
- Esztergom, Hungary
- Kistarcsa, Hungary
- Pécs, Hungary
- Sopron, Hungary
- Sestri Ponente, Italy
- Aosta, Italy
- Bolzano, Italy
- Foggia, Italy
- L’Aquila, Italy
- Milan, Italy
- Roggiano Gravina, Italy
- Roma, Italy
- Terrassa, Spain
- Barcelona, Spain
- Elche, Spain
- Langreo, Spain
- Madrid, Spain
- Murcia, Spain
- Oviedo, Spain
- Salamanca, Spain
- Valencia, Spain
- Zamora, Spain
- Newport, United Kingdom
- South Wales, United Kingdom
- Hull, United Kingdom
- Dundee, United Kingdom
- Haywards Heath, United Kingdom
- Czechia
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to explore more studies?
Explore studiesRelated studies
A 12-WEEK, MULTICENTER, OPEN-LABEL EXTENSION STUDY IN SUBJECTS WITH SCHIZOPHRENIA
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...